Scientists hunt for clues to why clozapine works for some with schizophrenia

NCT ID NCT05316883

Recruiting now Knowledge-focused Sponsor: Jimmi Nielsen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at 200 people with treatment-resistant schizophrenia who are starting clozapine. Researchers will measure immune markers in blood and spinal fluid, brain scans, and other tests before and after 12 weeks of treatment. The goal is to find biological signs that predict who will respond well to clozapine, which could help tailor treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clozapine
What this could lead to: If successful, this could help doctors identify which patients are most likely to respond to clozapine, leading to more personalized treatment for schizophrenia.
What could go wrong: This is an observational study focused on biomarkers, not a treatment trial. It may not directly improve outcomes, and results may not apply to all patients with schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC PARANOID PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

paranoid schizophrenia psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSYCHOSIS SCHIZOPHRENIA

Contacts and locations

Locations

Mental Health Services Glostrup, Unit for Complicated Schizophrenia
RECRUITING

Glostrup Municipality, Denmark, 2600, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.